CN113144176A - Skin wound repair composition containing plant extract and preparation method thereof - Google Patents

Skin wound repair composition containing plant extract and preparation method thereof Download PDF

Info

Publication number
CN113144176A
CN113144176A CN202110404575.XA CN202110404575A CN113144176A CN 113144176 A CN113144176 A CN 113144176A CN 202110404575 A CN202110404575 A CN 202110404575A CN 113144176 A CN113144176 A CN 113144176A
Authority
CN
China
Prior art keywords
pumpkin
aloe
parts
skin
repair composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110404575.XA
Other languages
Chinese (zh)
Inventor
韩丹
周艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital of Medical College of Xian Jiaotong University
Original Assignee
First Affiliated Hospital of Medical College of Xian Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of Medical College of Xian Jiaotong University filed Critical First Affiliated Hospital of Medical College of Xian Jiaotong University
Priority to CN202110404575.XA priority Critical patent/CN113144176A/en
Publication of CN113144176A publication Critical patent/CN113144176A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/446Superoxide dismutase (1.15)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/38Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y115/00Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001Superoxide dismutase (1.15.1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254Enzymes, proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41Anti-inflammatory agents, e.g. NSAIDs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)

Abstract

The invention provides a skin wound repair composition containing plant extracts, which comprises the following components in parts by weight: 10-15 parts of pumpkin-aloe composite extract, 0.01-0.1 part of superoxide dismutase and 0-90 parts of auxiliary components; the pumpkin-aloe compound extract is prepared by sealing and fermenting a mixture of pumpkin and aloe. The skin wound repair composition provided by the invention has a remarkable effect in the treatment of second-degree and third-degree skin burns and scalds.

Description

Skin wound repair composition containing plant extract and preparation method thereof
Technical Field
The invention belongs to the technical field of skin treatment medicines, and particularly relates to a skin wound repair composition containing plant extracts and a preparation method thereof.
Background
Burn and scald refers to the damage of body tissues, mainly skin, caused by heat such as boiling liquid (water, oil, soup), hot metal (liquid or solid), flame, steam and high temperature gas. It is mainly manifested as redness, swelling, blisters, peeling, pain, etc. of the skin at the burn and scald sites. The scald treatment device is generally divided into three degrees according to the scald depth, namely first-degree scald, second-degree scald and third-degree scald, wherein the first-degree scald only damages a epidermal layer, the injured skin turns red and swells, and hot and spicy pain is felt, but no blister appears, the second-degree scald only damages a corium layer, local redness and swelling are generated, heat is generated, pain is difficult to endure, obvious blisters exist, the third-degree scald is full-layer skin, fat below the skin, bones and muscles can be injured, and the scald treatment device presents yellow, waxy white and pain sense loss.
In the treatment of burns and scalds, the treatment of wound surfaces is the main part for treating burns and scalds, and local antibacterial drugs are important methods for avoiding invasive infection of the wound surfaces. The local antibacterial medicine is a main mode for treating burns and scalds, but except antibacterial treatment for third-degree burns and scalds, skin grafting operation is often required when the area is large or the injury is deep, the common skin grafting operation comprises two modes of autologous skin grafting and allogenic skin grafting, the autologous skin grafting needs to be carried out on the self healthy skin of a patient and then transplanted to the wound surface of the patient, but the wound surface of a large-area severe burn and scald patient is large, the autologous skin often cannot meet the grafting requirement, and the autologous skin can generate secondary damage, so that the infection probability is increased; the allogeneic skin transplantation usually adopts artificial skin, such as pig skin after cell removal treatment, but the current artificial skin technology development at home and abroad is immature, the performance is unstable, immunological rejection is easy to generate, the price is high, and ordinary people cannot bear high medical expenses fundamentally.
At present, treatment means for second-degree and third-degree scald patients at home and abroad are limited, the patients are mainly treated by antibacterial and vital sign support therapy and skin grafting treatment if the patients are serious, the wound healing infection risk of the patients is large, particularly, topical medicines are very limited, the requirements of the patients with serious burns and scalds are difficult to meet, and severe scars and abnormal pigments appear on the skin at the later stage of the second-degree and third-degree burns and scalds. Therefore, aiming at the problems in the prior art, a specific medicine for external application for patients with moderate burn and scald or severe burn and scald, which can quickly relieve symptoms and accelerate skin healing, needs to be found.
Disclosure of Invention
The invention aims to provide a skin wound repair composition and a preparation method thereof aiming at the problems in the prior art, and the skin wound repair dressing has a better skin repair function for patients with first-degree, second-degree and third-degree burns and scalds.
The purpose of the invention is realized by the following technical scheme:
on one hand, the skin wound repair dressing is provided, and comprises the following components in parts by weight: 10-15 parts of pumpkin-aloe composite extract, 0.01-0.1 part of superoxide dismutase and 0-90 parts of auxiliary components; the pumpkin-aloe compound extract is prepared by sealing and fermenting a mixture of pumpkin and aloe.
Preferably, the auxiliary component is selected from notoginseng injection, and the notoginseng injection is 0.5-1 part by weight, such as 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part or 1 part. The pseudo-ginseng injection has the effects of promoting blood circulation and removing blood stasis, and a large number of experiments prove that the pseudo-ginseng injection with 0.5-1 part of the pseudo-ginseng injection can prevent vascular embolism of a corium layer, prevent scar hyperplasia and relieve pain.
Preferably, the adjunct ingredient is selected from sterile water in a weight fraction of 60-90 parts, such as 60 parts, 65 parts, 68 parts, 70 parts, 75 parts, 78 parts, 80 parts, 82 parts, 85 parts, 87 parts, 88 parts, 89 parts or 90 parts. The pumpkin-aloe composite extract is diluted by using sterile water and then is made into spray for use, so that the use is more convenient.
Preferably, the adjunct ingredient is selected from collagen in a weight fraction of 3-5 parts, such as 3 parts, 4 parts, or 5 parts. The collagen is selected from human-like collagen, on one hand, the human-like collagen can form a protective film on the surface of skin to prevent skin wound infection, and on the other hand, the human-like collagen can increase the skin elasticity, prevent skin necrosis and skin color spot formation, and can keep the damaged skin smooth, fine, white and tender after being repaired.
Preferably, the accessory ingredient is selected from hyaluronic acid, the weight portion of hyaluronic acid is 1-5 parts, such as 1 part, 2 parts, 3 parts, 4 parts or 5 parts. Preferably, the hyaluronic acid is a small molecule hyaluronic acid. The hyaluronic acid is a human body own component, and after the small-molecule hyaluronic acid is added into the skin wound repair dressing, the small-molecule hyaluronic acid can rapidly permeate into the deep layer of the skin, and meanwhile, the small-molecule hyaluronic acid can carry other nutrient substances to permeate into the deep layer of the skin, so that the skin can be kept moist, and the regeneration and recovery of deep tissues of the skin are facilitated.
Preferably, the accessory ingredient is selected from the group consisting of chitosan oligosaccharide in a weight part of 1-5 parts, such as 1 part, 2 parts, 3 parts, 4 parts or 5 parts. The chitosan oligosaccharide can stimulate organisms and activate macrophages, and can effectively inhibit the occurrence of skin infection when being used in the skin wound repair dressing.
Preferably, the pumpkin-aloe composite extract adopts the proportion of pumpkin to aloe being 7: 4. Repeated experiments prove that the effect is best when the proportion of the pumpkin to the aloe is 7: 4.
Preferably, the pumpkin-aloe composite extract is prepared by the following method:
step 1: selecting tender pumpkin with green yellow, cleaning, removing pedicel, air drying, and mashing to obtain pumpkin paste; cleaning fresh aloe, air drying, mashing, mixing with the pumpkin paste, and fermenting in a sealed container for 6-18 months to obtain a fermentation product;
step 2: filtering the fermentation product, and collecting filtrate to obtain fructus Cucurbitae Moschatae-Aloe composite extract.
In a second aspect, a method for preparing a skin wound repair dressing is provided, which comprises the following steps:
step 1: selecting tender pumpkin with green yellow, removing pedicel, and mashing to obtain pumpkin paste; cleaning fresh aloe, air drying, mashing, mixing with the pumpkin paste, and fermenting in a sealed container for 6-18 months to obtain a fermentation product;
step 2: filtering the fermentation product, and collecting filtrate to obtain fructus Cucurbitae Moschatae-Aloe composite extract;
and step 3: adding superoxide dismutase and auxiliary components into the pumpkin-aloe composite extract, uniformly mixing, sterilizing and filling for later use.
Preferably, the weight ratio of the pumpkin puree to the aloe vera is 7: 4.
Preferably, the ambient temperature outside the sealed container in step 1 is maintained at 20-30 ℃.
In a third aspect, a method for using the skin wound repair composition is provided, which comprises: the skin wound repairing dressing is smeared on the surface of damaged skin, the gauze is wetted after the skin wound repairing dressing is wrapped by the gauze, the gauze is repeatedly sprayed on the skin wound repairing dressing every 3-4 hours, the skin surface is kept in a wet state continuously, the gauze is replaced every three days, and after the skin wound repairing dressing is continuously used for 1 month, the medicine application is stopped or the spraying times per day are reduced or the treatment time is properly prolonged according to the skin recovery condition.
In a fourth aspect, a skin wound repair patch is provided, comprising the skin wound repair composition and a dressing, wherein the skin wound repair composition is adsorbed on the dressing, and the dressing is selected from dry gauze, oily gauze, interactive dressing, silver dressing, calcium alginate dressing, foam dressing, hydrocolloid dressing, and hydrogel dressing.
Preferably, the oily yarn comprises glycerol or triglycerides. Avoid the adhesion of the dressing and the wound.
Preferably, the interactive dressing contains an acrylate polymer activated by ringer's fluid. The ringer's solution can be released in 24 hours, and the wound can be cleaned continuously, actively and effectively.
Preferably, the silver dressing contains silver ions. Can kill bacteria, control wound infection, and accelerate wound healing.
Preferably, the calcium alginate dressing comprises calcium alginate. The calcium alginate dressing forms smooth gel after contacting with wound seepage and oozing blood, protects the wound surface and effectively promotes wound healing.
Preferably, the surface of the foam dressing is covered with a polyurethane semipermeable membrane, and the foam dressing has high liquid seepage absorption capacity, can reduce wound adhesion, promote wound healing and buffer external pressure.
Preferably, the hydrocolloid dressing utilizes a closed moisturizing principle, the hydrophilic CMC particles are contacted with wound exudation, a layer of wet gel is formed on the surface of a wound surface, a moist environment is continuously created, and the hydrocolloid dressing is not adhered to the wound surface.
Preferably, the hydrogel dressing contains a hydrophilic polyurethane polymer, automatically adjusts the wettability of the wound, has a small capacity of absorbing exudate, is non-sticky to the wound and is easy to remove.
Compared with the prior art, the invention has the beneficial effects that:
the skin wound repair composition provided by the invention mainly adopts pumpkin-aloe composite extract as an active ingredient, other auxiliary ingredients are used as auxiliary synergistic ingredients to perform synergistic action, and aloe is a polysaccharide phenolic compound, has the effects of expanding blood vessels, promoting blood circulation, sterilizing and diminishing inflammation, decomposing dead and infected tissue cells and promoting cell proliferation and regeneration, has a good treatment effect on skin superficial injuries such as incised wound, scald, bruise and sprain, and reduces scars.
The pumpkin fruits have sweet and warm nature and taste, and can tonify the middle-jiao and Qi by internal administration and diminish inflammation, relieve pain and remove toxicity by external application. In the process of developing the specific medicine for treating the burns and scalds, the inventor finds that the pumpkin has a good effect on treating the burns and scalds, but when the pumpkin extract is used for treating patients with second-degree and third-degree burns and scalds, the pain is strong, the antibacterial effect is not good enough, and the skin is easy to infect.
The superoxide dismutase can remove free radicals in vivo and accelerate wound healing, and can remarkably shorten the healing time of skin wounds after being compounded with the pumpkin-aloe composite extract.
In addition, in the process of preparing the skin wound repair composition, the pumpkin is subjected to sealed fermentation, multiple experiments show that the prepared pumpkin extract is unstable in quality and often smells and becomes sour, after the aloe is added, the antibacterial effect of the aloe can keep the product stable in quality, the effect is better, and the pumpkin extract and the aloe extract play a synergistic effect in the treatment of severe burns and scalds and particularly severe burns and scalds. The pumpkin extract can relieve fire toxin, eliminate free radicals in vivo, tonify middle-jiao and Qi, expand blood vessels, promote blood circulation, sterilize and diminish inflammation, promote cell proliferation and regeneration, and can lead damaged skin tissues to be rapidly regenerated.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
The embodiment provides a skin wound repair composition which comprises the following components in parts by weight: 15 parts of pumpkin-aloe composite extract and 0.05 part of superoxide dismutase; the pumpkin-aloe compound extract is prepared by sealing and fermenting a mixture of pumpkin and aloe. In some embodiments, the weight portion of the pumpkin-aloe complex extract is 10, 11, 12, 13 or 14. In some embodiments, the weight portion of the superoxide dismutase is 0.01 parts, 0.02 parts, 0.03 parts, or 0.04 parts. In some embodiments, the pumpkin-aloe complex extract is obtained by using pumpkin and aloe in a ratio of 7: 4. Repeated experiments prove that the effect is best when the proportion of the pumpkin to the aloe is 7: 4.
Example 2
The embodiment provides a skin wound repair composition which comprises the following components in parts by weight: 10 parts of pumpkin-aloe composite extract, 0.05 part of superoxide dismutase and 0.5 part of pseudo-ginseng injection. In some embodiments, the weight part of the notoginseng injection is 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts or 1 part. The pseudo-ginseng injection has the effects of promoting blood circulation and removing blood stasis, and a large number of experiments prove that the pseudo-ginseng injection with 0.5-1 part of the pseudo-ginseng injection can prevent vascular embolism of a corium layer, prevent scar hyperplasia and relieve pain.
Example 3
The embodiment provides a skin wound repair composition which comprises the following components in parts by weight: 10 parts of pumpkin-aloe composite extract, 0.05 part of superoxide dismutase and 60 parts of sterile water. In some embodiments, the weight parts of the sterile water are 65 parts, 68 parts, 70 parts, 75 parts, 78 parts, 80 parts, 82 parts, 85 parts, 87 parts, 88 parts, 89 parts, or 90 parts. The pumpkin-aloe composite extract is diluted by using sterile water and then is made into spray for use, so that the use is more convenient.
Example 4
The embodiment provides a skin wound repair composition which comprises the following components in parts by weight: 12 parts of pumpkin-aloe composite extract, 0.02 part of superoxide dismutase and 4 parts of collagen. In some embodiments, the collagen is present in an amount of 3.5 parts, 4 parts, 4.5 parts, or 5 parts by weight. The collagen is selected from human-like collagen, on one hand, the human-like collagen can form a protective film on the surface of skin to prevent skin wound infection, and on the other hand, the human-like collagen can increase the skin elasticity, prevent skin necrosis and skin color spot formation, and can keep the damaged skin smooth, fine, white and tender after being repaired.
Example 5
The embodiment provides a skin wound repair composition which comprises the following components in parts by weight: 14 parts of pumpkin-aloe complex extract, 0.03 part of superoxide dismutase and 1 part of hyaluronic acid, wherein in some embodiments, the weight part of the collagen is 2 parts, 3 parts, 4 parts or 5 parts. Preferably, the hyaluronic acid is a small molecule hyaluronic acid. The hyaluronic acid is a human body own component, and after the small-molecule hyaluronic acid is added into the skin wound repair composition, the small-molecule hyaluronic acid can rapidly permeate into the deep layer of the skin, and meanwhile, the small-molecule hyaluronic acid can carry other nutrient substances to permeate into the deep layer of the skin, so that the skin can be kept moist, and the regeneration and recovery of deep tissue of the skin are facilitated.
Example 6
The embodiment provides a skin wound repair composition which comprises the following components in parts by weight: 11 parts of pumpkin-aloe composite extract, 0.04 part of superoxide dismutase and 2 parts of chitosan oligosaccharide. In some embodiments, the weight portion of the chitosan oligosaccharide is 1 part, 2.5 parts, 3 parts, 4 parts, or 5 parts. The chitosan oligosaccharide can stimulate organisms and activate macrophages, and can effectively inhibit the occurrence of skin infection when being used in the skin wound repair composition.
Example 7
The embodiment provides a preparation method of a pumpkin-aloe composite extract, which is prepared by the following steps:
step 1: selecting tender pumpkin with green yellow, cleaning, removing pedicel, air drying, and mashing to obtain pumpkin paste; cleaning fresh aloe, air drying, mashing, mixing with the pumpkin paste, and fermenting in a sealed container for 6-18 months to obtain a fermentation product;
step 2: filtering the fermentation product, and collecting filtrate to obtain fructus Cucurbitae Moschatae-Aloe composite extract.
Example 8
The embodiment provides a preparation method of a skin wound repair composition, which comprises the following steps:
step 1: selecting tender pumpkin with green yellow, removing pedicel, and mashing to obtain pumpkin paste; cleaning fresh aloe, air drying, mashing, mixing with the pumpkin paste, and fermenting in a sealed container for 6-18 months to obtain a fermentation product;
step 2: filtering the fermentation product, and collecting filtrate to obtain fructus Cucurbitae Moschatae-Aloe composite extract;
and step 3: adding superoxide dismutase and auxiliary components into the pumpkin-aloe composite extract, uniformly mixing, sterilizing and filling for later use.
In some embodiments, the weight ratio of the pumpkin puree to the aloe vera is 7: 4.
In some embodiments, the ambient temperature outside the sealed container in step 1 is maintained at 20-30 ℃.
Example 9
The embodiment provides a skin wound repair patch, which comprises the skin wound repair composition and a dressing, wherein the skin wound repair composition is adsorbed on the dressing, and the dressing is selected from dry gauze.
In some embodiments, the dressing is selected from the group consisting of oil gauze, interactive dressing, silver dressing, calcium alginate dressing, foam dressing, hydrocolloid dressing, hydrogel dressing.
In some embodiments, the oil yarn comprises glycerol or triglycerides. Avoid the adhesion of the dressing and the wound.
In some embodiments, the interactive dressing contains an acrylate polymer that is activated by ringer's fluid. The ringer's solution can be released in 24 hours, and the wound can be cleaned continuously, actively and effectively.
In some embodiments, the silver dressing contains silver ions. Can kill bacteria, control wound infection, and accelerate wound healing.
In some embodiments, the calcium alginate dressing comprises calcium alginate. The calcium alginate dressing forms smooth gel after contacting with wound seepage and oozing blood, protects the wound surface and effectively promotes wound healing.
In some embodiments, the surface of the foam dressing is covered with a polyurethane semipermeable membrane, and the foam dressing has high liquid seepage absorption capacity, can reduce wound adhesion, promote wound healing and buffer external pressure.
In some embodiments, the hydrocolloid dressing utilizes a closed moisturizing principle, the hydrophilic CMC particles act in contact with wound exudation, and a layer of moist gel is formed on the surface of a wound surface, so that a moist environment is continuously created and the hydrocolloid dressing does not adhere to the wound surface.
In some embodiments, the hydrogel dressing comprises a hydrophilic polyurethane polymer, self-regulates the wettability of the wound, has a low capacity to absorb exudate, is non-adhesive to the wound, and is easily removable.
The pharmacodynamics of the burn and scald spray of the invention is further evaluated by the following comparative experiments:
first, influence experiment to scald model
1. Purpose of study
An experimental water bath scald rat model is adopted to evaluate the treatment effect of the skin wound repair composition on scalds.
2. Experimental Material
1) The burn and scald preparation disclosed in the embodiments 1-6 of the invention is named as preparation 1, preparation 2, preparation 3, preparation 4, preparation 5 and preparation 6 respectively, is a light brown liquid medicine and is provided by professor of the beauty of the first subsidiary hospital of the university of western's transportation;
2) meibao moist burn cream is produced by Shantou Meibao pharmaceutical Co., Ltd, and has the batch number: 20200624, respectively;
3) lactated ringer's injection: sichuan Koran pharmaceutical Co., Ltd, batch number: B12071012.
3. laboratory animal
SD rats, 80, all-male, 180-.
4. Experimental methods
4.1 molding method: male Sprague-Dawley rats were acclimatized for 1 week and were fed freely. Pentobarbital sodium (40mg/kg) for rat, performing intraperitoneal injection and anesthesia, shearing hair on the back, and obtaining an area of about 5 x 5cm2Then, the wool is removed with 8% sodium sulfide, and the residual sodium sulfide is removed by warm water washing. The depilated back skin was then immersed in a 100 ℃ constant temperature water bath for 15 seconds, resulting in a deep scald, heavy scald model. After scald for 10min, the skin is sucked dry with gauze, and 5ml of lactated ringer's injection is injected into abdominal cavity to supplement water.
4.2 animal groups and administrations: after the model is made, rats with obvious red swelling and exudation on the unhairing part are selected for experiments, and the rats are randomly divided into 8 groups according to the weight, namely a model control group, a Meibao moist burn cream control group (called Meibao moist control group for short), an experiment group 1, an experiment group 2, an experiment group 3, an experiment group 4, an experiment group 5 and an experiment group 6, wherein each group comprises 10 rats. After 6 hours of molding, the scald part is coated, the model control group is coated with normal saline for 0.5 ml/time, the MEIBAOWEI control group is coated with MEIBAOWEI burn cream, the experiment groups 1-6 are correspondingly coated with corresponding liquid medicines of the preparations 1-6, and the liquid medicines are coated on the skin of the scald part for 3 times every day (the coating time is 8: 00-9: 00, 14: 00-15: 00, 20: 00-21: 00 respectively), 1ml each time, and continuously for 20 days.
4.3 Observation index
4.3.1 scab time: the scab condition of the scald part of the rats is observed and recorded every day, and the scab time of each group of rats is recorded. The results are shown in Table 2.
4.3.2 wound healing rate: and (3) pasting the parchment paper on the wound surface at 5d, 10d, 15d and 20d after the scald to draw a scabbing wound surface graph, and representing the scabbing area of the wound surface by the weight of the parchment paper on the wound surface. And taking the area of the scab wound surface of the 5 th d as an initial area, comparing the area of the scab wound surface of the wound surfaces of the 10 th, 15 th and 20 th d, and calculating the wound surface healing rate of each group of animals at different time points after the scald according to the following formula. The results are shown in Table 3.
The wound healing rate (area of initial scald-area of non-healed wound)/area of initial scald is 100%
4.3.3 detection of wound surface pathomorphology: the drug is administered for 1 hour at the last time, rats are killed after the scab area of the wound surface is measured, the skin of the scald part is left for routine pathological examination, and the tissue morphology of the wound surface and the proliferation and migration conditions of keratinocytes in the healing process of the scald wound surface are observed.
The specific method comprises the following steps: washing the scalded skin tissue with tap water overnight before dehydration after taking the material, dehydrating with ethanol of each stage by using a full-automatic dehydrator, enabling TO transparent liquid TO be transparent, and waxing for two times; embedding with normal paraffin by an embedding machine; slicing with a rotary slicer to 5 μm; HE dyeing; the sections were transparent in TO clear solution and mounted on Canadian gum for microscopic examination. The above specimens were all performed according to SOP program of pathological examination in the department of pathology in the first subsidiary hospital of the university of transportation of Xian. Dehydration, trimming, embedding, sectioning, HE staining, mounting, etc., and finally microscopic examination under 10X 10 times light (see Table 1 for diagnostic criteria).
TABLE 1 tissue lesion grading Scoring criteria
Figure RE-GDA0003103018330000081
4.4 statistical analysis: data are expressed as "mean. + -. standard deviation"
Figure RE-GDA0003103018330000082
It is shown that each group of data is normally distributed and subjected to one-way ANOVA, and t test is performed when the variance is uniform and t' test is performed when the variance is irregular.
5. Results of the experiment
5.1 influence of Chinese medicinal liquid on scabbing time of experimental water-bath scald model
TABLE 2 influence of Chinese medicinal liquid on experimental water-bath scald model scabbing time
Figure RE-GDA0003103018330000083
Group of Quantity (only) Incrustation time (d)
Model control group 10 8.1±1.5
Meibao wet control group 10 6.2±1.2
Experimental group 1 10 4.9±0.8
Experimental group 2 10 4.8±0.9
Experimental group 3 10 5.7±1.1
Experimental group 4 10 5.1±0.7
Experimental group 5 10 4.9±0.8
Experimental group 6 10 5.2±1.0
Note: p <0.05 compared to model control; p < 0.01; p <0.001
As can be seen from Table 2, compared with the model control group and the MEIBAOHUI control group, the scab forming time of the experimental groups 1-6 is obviously shortened, and the statistical significance (P >0.05) is significant, which suggests that the experimental groups 1-6 have the effect of obviously promoting the scab forming of the burned skin, wherein the scab promoting effect of the experimental group 1 is the most obvious.
5.2 Effect of Chinese medicinal liquid on the healing rate of the wound surface of the experimental water-bath scald model
TABLE 3 influence of Chinese medicinal liquid on the healing rate of experimental water-bath scald model wound
Figure RE-GDA0003103018330000091
Figure RE-GDA0003103018330000092
Note: p <0.05 compared to model control; p < 0.01; p <0.001
As can be seen from table 3, compared with the model control group and the masu-bao-shi control group, the wound healing rate of the experimental group 1-6 is significantly higher than that of the model control group and the masu-bao-shi control group at the 10 th day of modeling, and the statistical significance (P >0.05) is significant; molding 15d, wherein the healing rate of the experimental groups 1-6 exceeds 85%; modeling 20d, full healing of experimental groups 1-6. The experimental groups 1 to 6 are all prompted to have the effect of remarkably promoting the healing of the scald wound.
Secondly, the analgesic effect of the liquid medicine-the influence on the hot plate licking reaction of the mouse
1. Purpose of study
The influence of the skin wound repair composition on pain response caused by thermal stimulation is considered, and the analgesic effect of the composition is evaluated.
2. Experimental Material
1) The skin wound repair compositions described in embodiments 1 to 6 of the present invention are respectively named as preparation 1, preparation 2, preparation 3, preparation 4, preparation 5, and preparation 6, and respectively correspond to experimental group 1, experimental group 2, experimental group 3, experimental group 4, experimental group 5, and experimental group 6.
2) Meibao moist burn cream is produced by Shantou Meibao pharmaceutical Co., Ltd, and has the batch number: 20200624, respectively;
3) common white mice, female, with body weight (20 + -2) g, were provided by the research center for laboratory animals in Shanxi province.
3. Experimental methods
Adjusting the temperature of the water in the constant-temperature water bath tank to 55 +/-0.5 ℃, putting a 500ml beaker into the constant-temperature water bath tank, enabling the bottom of the beaker to be in contact with the water surface, preheating for 10 minutes, and taking one mouse to put into the beaker every time. The time(s) required from the placement of the beaker to the occurrence of licking (i.e. the pain threshold) is recorded, and if the pain threshold is between 5 and 30s, the animal is in accordance with the experimental requirements. And taking 40 female mice with qualified preselected pain threshold values, dividing the female mice into 8 groups according to a random method, namely a blank group, a Meibao wet control group, an experimental group 1, an experimental group 2, an experimental group 3, an experimental group 4, an experimental group 5 and an experimental group 6, wherein 5 female mice in each group are repeatedly measured for the pain threshold values twice according to the method, and taking the average value of the normal pain threshold values twice to serve as the pain threshold value before administration of the mice. The medicines of each group are respectively and uniformly coated on four limbs of mice of a corresponding experimental group, each limb is 0.2ml, the pain threshold value is measured 1h and 1.5h after the medicine is administered, and the medicine is not administered in a blank group. The pain threshold differences of the Meibao wet control group, the experimental group 1-the experimental group 6 and the blank group were compared and statistically processed by t-test.
The results show that: compared with the blank group, the experimental group 1-the experimental group 6 and the MEIBAO control group have the tendency of prolonging the pain threshold value of hot plate pain-causing reaction of the mice, but the effect of prolonging the pain threshold value of hot plate pain-causing reaction of the mice of the experimental group 1-the experimental group 6 is more obvious than that of the MEIBAO control group. The experimental groups 1 to 6 are prompted to have better analgesic effect. The results are shown in Table 4.
TABLE 4 statistical results of hot-plate-induced pain response in mice: (
Figure RE-GDA0003103018330000101
n=10)
Figure RE-GDA0003103018330000102
Examples of treatments
1. The first patient: female, 43 years old, Honda people in Xian city, with the left hand scalded by hot oil in 12 months in 2019, has the diagnosis of blister, erosion and red swelling, is diagnosed as 'second degree scald', and can be cured after 18 days of continuous medication without scar formation after 6 months.
2. The second patient: female, 22 years old, Weinan city Dali county, was seriously scalded by boiled water in 2019 for 7 months, had bullous blisters and severe pain, was diagnosed as "second degree scald", had pain relieved after the wound was dosed, began to scab after 3 days, and healed after 15 days. After 6 months no scar was formed.
3. The third patient: male, 35 years old, Fuping county in Weinan city, working in 2019 for 5 months, the hands are carelessly burned by chemical agents, the upper limb skin ulceration and red swelling are serious, the second-degree scald is diagnosed, the pain burning feeling is obviously reduced after the medicine is taken, the skin starts to scab after 10 days, the red swelling is gradually subsided, and the disease is cured after 26 days of continuous medicine taking. After 6 months, scars were not evident, and some skin had mild hypopigmentation.
In summary, it can be seen from the combined results of the above experiments and treatment examples that: the skin wound repair composition containing the plant extract has the remarkable effects of promoting scabbing of scalded skin and promoting healing of scalded wound, has a good analgesic effect, and shows a remarkable treatment effect on the scalded skin. Therefore, the present application has a significant technical advance.
The above description is only an embodiment of the present application, but the scope of the present application is not limited thereto, and any changes or substitutions within the technical scope of the present disclosure should be covered by the scope of the present application. Therefore, the protection scope of the present application shall be subject to the protection scope of the claims.

Claims (10)

1. A skin wound repair composition containing plant extracts is characterized by comprising the following components in parts by weight: 10-15 parts of pumpkin-aloe composite extract, 0.01-0.1 part of superoxide dismutase and 0-90 parts of auxiliary components; the pumpkin-aloe compound extract is prepared by sealing and fermenting a mixture of pumpkin and aloe.
2. The composition for repairing a skin wound surface according to claim 1, wherein the auxiliary component is selected from a pseudo-ginseng injection, and the pseudo-ginseng injection is 0.5 to 1 part by weight.
3. The dermabrasion repair composition according to claim 1, wherein said auxiliary component is selected from sterile water, and the weight portion of said sterile water is 60-90 portions.
4. A dermoidal wound repair composition according to claim 1, wherein said adjunct ingredient is selected from the group consisting of collagen in an amount of 3 to 5 parts by weight.
5. The skin wound repair composition according to claim 1, wherein the auxiliary component is selected from hyaluronic acid, and the weight portion of hyaluronic acid is 1-5 portions.
6. The dermabrasion repair composition according to claim 1, wherein said auxiliary component is selected from the group consisting of chitosan oligosaccharide, and the weight portion of said chitosan oligosaccharide is 1-5.
7. The skin wound repair composition of claim 1, wherein the pumpkin-aloe complex extract is produced with a pumpkin to aloe ratio of 7: 4.
8. The skin wound repair composition according to claim 1, wherein the pumpkin-aloe complex extract is prepared by the following method:
step 1: selecting tender pumpkin with green yellow, cleaning, removing pedicel, air drying, and mashing to obtain pumpkin paste; cleaning fresh aloe, air drying, mashing, mixing with the pumpkin paste, and fermenting in a sealed container for 6-18 months to obtain a fermentation product;
step 2: filtering the fermentation product, and collecting filtrate to obtain fructus Cucurbitae Moschatae-Aloe composite extract.
9. A preparation method of a skin wound repair composition containing plant extracts is characterized by comprising the following steps:
step 1: selecting tender pumpkin with green yellow, removing pedicel, and mashing to obtain pumpkin paste; cleaning fresh aloe, air drying, mashing, mixing with the pumpkin paste, and fermenting in a sealed container for 6-18 months to obtain a fermentation product;
step 2: filtering the fermentation product, and collecting filtrate to obtain fructus Cucurbitae Moschatae-Aloe composite extract;
and step 3: adding superoxide dismutase and auxiliary components into the pumpkin-aloe composite extract, uniformly mixing, sterilizing and filling for later use.
10. The method of claim 9, wherein the ambient temperature outside the sealed container in step 1 is maintained at 20-30 ℃.
CN202110404575.XA 2021-04-15 2021-04-15 Skin wound repair composition containing plant extract and preparation method thereof Pending CN113144176A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110404575.XA CN113144176A (en) 2021-04-15 2021-04-15 Skin wound repair composition containing plant extract and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110404575.XA CN113144176A (en) 2021-04-15 2021-04-15 Skin wound repair composition containing plant extract and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113144176A true CN113144176A (en) 2021-07-23

Family

ID=76867541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110404575.XA Pending CN113144176A (en) 2021-04-15 2021-04-15 Skin wound repair composition containing plant extract and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113144176A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008088105A (en) * 2006-10-02 2008-04-17 Eikodo Honten:Kk Cosmetic for skin or hair
CN101601799A (en) * 2009-07-17 2009-12-16 梁小松 A kind of medicine that is used for the treatment of scald
CN107596171A (en) * 2017-10-16 2018-01-19 孙振惠 A kind of skin wound care formulations and preparation method thereof
CN108159203A (en) * 2017-12-23 2018-06-15 董晓 A kind of preparation method for the spray that scald is promoted to repair

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008088105A (en) * 2006-10-02 2008-04-17 Eikodo Honten:Kk Cosmetic for skin or hair
CN101601799A (en) * 2009-07-17 2009-12-16 梁小松 A kind of medicine that is used for the treatment of scald
CN107596171A (en) * 2017-10-16 2018-01-19 孙振惠 A kind of skin wound care formulations and preparation method thereof
CN108159203A (en) * 2017-12-23 2018-06-15 董晓 A kind of preparation method for the spray that scald is promoted to repair

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ZHIWEN HAI等: "Evaluation of the Treatment Effect of Aloe vera Fermentation in Burn Injury Healing Using a Rat Model", 《MEDIATORS OF INFLAMMATION》 *
徐海波等: "《中药药理学》", 31 August 2020, 中国医药科技出版社 *
杨胜群等: "中药在烧烫伤治疗中的应用及作用机制研究进展", 《中南药学》 *
柴可夫: "《中国食材考》", 31 July 2013, 中国中医药出版社 *
陈耀华: "《人类健康的金钥匙-壳寡糖》", 31 August 2008, 中国医药科技出版社 *

Similar Documents

Publication Publication Date Title
CN104288828B (en) A kind of medical bio presses down scar reduce wrinkle dressing and preparation method thereof
JP2019517533A (en) External pharmaceutical composition for treatment of various wound wounds of skin and preparation method thereof
Khorasani et al. The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study
WO2010042991A1 (en) Methods of treatment utilising glucan formulations
CN106693034A (en) Preparation method of pollution-free surgical dressing for sterilizing and stopping bleeding
CN113520896A (en) Composition with acne removing and acne mark repairing functions and preparation method thereof
WO2017080048A1 (en) Film spraying agent for superfical burns and preparation method therefor
CN109700998A (en) A kind of compound skin injury regeneration renovation agent and preparation method thereof
CN114848884B (en) Polyurethane foam dressing and preparation method thereof
CN107441340B (en) Hand and foot chap cream for relieving swelling, pain and itching and nourishing skin and preparation method thereof
CN117297996A (en) Hirudin freeze-dried mask and preparation method thereof
CN113144176A (en) Skin wound repair composition containing plant extract and preparation method thereof
Abid et al. The efficacy of a new paste formulation as an alternative therapeutic agent for traumatic ulcers
CN112057681B (en) Composition containing bioglass ceramics and application thereof in scar repair
CN108853369B (en) Preparation method and application of natural plant antibacterial liquid PAMs hydrogel patch
CN110624032A (en) Ointment for treating burns and scalds and preparation method thereof
TWM610166U (en) Microcapsule structure
CN107982300B (en) Spray and preparation method and application thereof
KR20090107339A (en) Gel paste for treatment an ucler including an extract of elm tree and preparing method
CN110433236B (en) Traditional Chinese medicine composition for promoting wound healing and preparation method and application thereof
CN114886794B (en) Composition with anti-inflammatory and antioxidant effects and application thereof
CN102178795B (en) External medicine for treating burns and scalds and preparation method of medicine
CN114984294A (en) Dressing and preparation method thereof
CN112245484A (en) Spray for treating burns and scalds through external application
Sikka et al. Modern developments in burn wound dressing

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination